

PTO/SB/088 (04-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)	<b>Complete if Known</b>		
	Application Number	10/621,027	
	Filing Date	July 16, 2003	
	First Named Inventor	Nai-Kong Cheung	
	Art Unit	1623	
	Examiner Name	Jason H. Johnsen	
Attorney Docket Number	639-B-PCT-US		
Sheet 1	of 1		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Eso	1	Search Report prepared by the Norwegian Patent Office, dated May 4, 2005	
Eso	2	Hong et al., "Mechanism by Which Orally Administered $\beta$ -1,3-Glucans Enhance the Tumoricidal Activity of Antitumor Monoclonal Antibodies in Murine Tumor Models", Journal of Immunology, Vol. 173, No. 5, Pages 797-806 (2004)	
Eso	3	Ostroff et al., "Immune-Enhancing Effects of Oral Yeast $\beta$ 1,3/1,6 Glucans", American Chemical Society, Vol. 225, No. 1-2, pp. AGFD 8 (2003)	
Eso	4	Allendorf et al., "Macrophages shuttle orally administered $\beta$ -glucan to potentiate the CR3-dependent tumoricidal effects of monoclonal antibodies in mouse tumor models", FASEB Journal, Vol. 17, No. 7, Page C128 (2004)	
Eso	5	Papila et al., "The Effect of oral $\beta$ -glucan in addition to systemic chemotherapy on the leukocyte values with oral mucositis in the patients with head-neck tumors", International Review of Allergology & Clinical Immunology, Vol 10, No. 2, Pages 59-61 (2004)	

Examiner Signature	<i>Eric S. John</i>	Date Considered	12/19/06
--------------------	---------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	Nai-Kong Cheung
Art Unit	1623
Examiner Name	Jason H. Johnson
Attorney Docket Number	639-B-PCT-US

Sheet 1of 1**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO	11	Kidd, P., "The Use of Mushroom Glucans and Proteoglycans in Cancer Treatment", Alternative Medicine Review, Vol. 5, No. 1, Pages 4-27 (2000)	
	12	Hanaue, H. et al, "Effects of Oral Lentinan on T-Cell Subsets in Periphe Venous Blood", Clinical Therapeutics, Vol. 5 (1989)	
	13	Suzuki, M. et al, "Antitumor and Immunological Activity of Lentinan in Comparison with LPS", International Society of Pharmacology, Ltd., Pages 463-468 (1994)	
	14	Cheung, N.; Modak, S.; "Oral (1-3), (1-4)-B-D-Glucan Synergizes with Antiganglioside GD2 Monoclonal Antibody 3F8 in the Therapy of Neuroblastoma", Clinical Cancer Research, Vol. 8, Pages 1217-1223 (2002)	
	15	Chihara, G. et al., "Antitumor and Metastasis-Inhibitory Activities of Lentinan as an Immunomodulator: An Overview", Cancer Detection and Prevention Supplement, Vol. 1, Pages 423-443 (1987)	
✓	16	Mayer, L.; Shao, L., "Therapeutic Potential of Oral Tolerance", Nature Reviews Immunology, Vol. 4, Pages 407-419 (2004)	

Examiner Signature	<i>Eric S. Olson</i>	Date Considered	12/19/06
--------------------	----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (04-03)

Approved for use through 04/30/2003, OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	Nai-Kong Cheung
Art Unit	1623
Examiner Name	Jason H. Johnsen
Attorney Docket Number	639-B-PCT-US

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESD	1	PCT International Search Report for Sloan-Kettering Institute for Cancer Research, Int'l Application No. PCT/US04/23099, Filed July 16, 2004, Dated February 28, 2005	
	2	Babineau, T. et al., "Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High-Risk Surgical Patients", Annals of Surgery, Vol. 220, No. 5, Pages 601-609 (1994)	
	3	Babineau, T. et al., "A Phase II Multicenter, Double-blind, Randomized, Placebo-Controlled Study of Three Dosages of an Immunomodulator (PGG-Glucan) in High Risk Surgical Patients", Arch Surg, Vol. 129, Pages 1204-1210 (1994)	
	4	Arturson, G.; Wallenius, G., "The Renal Clearance of Dextran of Different Molecular Sizes in Normal Humans", Scandina J Clin & Lab Investigation, Vol. 1, Pages 81-86 (1964)	
	5	Dellinger, E., et al., "Effect of PGG-glucan on the Rate of Serious Postoperative Infection or Death Observed After High-Risk Gastrointestinal Operations", Arch Surg, Vol 134, Pages 977-983 (1999)	
	6	Arturson, G. et al., "Intravascular Persistence and Renal Clearance of Dextran of Different Molecular Sizes in Normal Children", Arch Dis Childh., Vol. 41, Pages 168-172 (1966)	
	7	Sortwell, R. et al., "Chronic Intravenous Administration of Lentinan to the Rhesus Monkey", Toxicology Letters, Vol. 9, Pages 81-85 (1981)	
	8	Shimazu, H. et al., "Intravenous chronic toxicity of lentinan in rats: 6-month treatment and 3-month recovery", National Library of Medicine (PubMed), J Toxicol Sci, Pages 33-57 (1980)	
	9	Mehvar, R., "Recent Trends in the Use of Polysaccharides for Improved Delivery of Therapeutic Agents: Pharmacokinetic and Pharmacodynamic Perspectives", Current Pharmaceutical Biotechnology, Vol. 4, Pages 283-302 (2003)	
✓	10	Hanaue, H. et al., "Basic Studies on Oral Administration of Lentinan (I)", J. Jpn. Cancer Ther., Vol. 8, Pages 1566-1571 (1989)	

Examiner Signature	<i>Eric S. Olson</i>	Date Considered	12/19/06
--------------------	----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

*(Use as many sheets as necessary)*

Sheet 1

of 2

**Complete if Known**

Application Number	10/621.027
--------------------	------------

Filing Date	July 16, 2003
-------------	---------------

First Named Inventor	Nai-Kong Chueng
----------------------	-----------------

### Art Unit

Examiner Name \_\_\_\_\_

Attorney Docket Number	639-B-PCT-US
------------------------	--------------

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1*
		Country Code <sup>2</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
ESO	2	WO 01/62283 A2	02/02/2000	Raa, et al.		

Examiner Signature	<i>Eric L. Olson</i>	Date Considered	12/19/06
--------------------	----------------------	-----------------	----------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**



PTO/SB/088 (04-03)  
Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/621,027		
		Filing Date	July 16, 2003		
		First Named Inventor	Nai-Kong CHEUNG		
		Art Unit			
Examiner Name					
Sheet	2	of	2	Attorney Docket Number	639-B-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO	3	Ross, et al. Therapeutic intervention with complement and beta-glucan in cancer, Immunopharmacology 42(1999), 61-74	
ESO	4	Vetvicka, et al. Pilot Study: Orally-administered Yeast beta-(1,3)-glucan prophylactically protect against anthrax infection and cancer in mice. Journ Ameri Nutraceutical Assoc, Vol. 5:2, April 22, 2002	
ESO	5	Cheung, N.K. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunother. 2002 Nov; 51(10):557-64	
ESO	6	Suzuki, et al. Effect of orally administered beta-glucan on macrophage function in mice. Int. J. Immunopharmacology 12:6, 675-684, 1990	

Examiner Signature	<i>Eui S. Odeon</i>	Date Considered	12/19/06
--------------------	---------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/621,027
Filing Date	July 16, 2003
First Named Inventor	Nai-Kong Chueng
Art Unit	
Examiner Name	
Attorney Docket Number	639-B-PCT-US

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
E50	1	WO 2004/014320 A2	02/19/2004	Ostroff, et al.		
	2	WO 2004/014320 A3	02/19/2004	Ostroff, et al.		
	3	WO 2004/021994 A2	03/18/2004	Ostroff, et al.		
	4	WO 2004/021994 A3	03/18/2004	Ostroff, et al.		


Examiner Signature	<i>Eric S. Olsen</i>	Date Considered	12/19/06
-----------------------	----------------------	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/621,027		
		Filing Date	July 16, 2003		
		First Named Inventor	Nai-Kong CHEUNG		
		Art Unit			
		Examiner Name			
Sheet	1	of	2	Attorney Docket Number	639-B-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO	1	S. Tsukagoshi, Y. Hashimoto, G. Fujii, H. Kobayashi, K. Nomoto, and K. Orita, Krestin (PSK). Cancer Treat. Rev. 11:131-155, 1984.	
	2	H. Nanba, H. and H. Kuroda, Antitumor mechanisms of orally administered shiitake fruit bodies. Chem. Pharm. Bull. (Tokyo) 35:2459-2464, 1987.	
	3	H. Nanba, H., K. Mori, T. Toyomasu, and H. Kuroda, Antitumor action of shiitake (Lentinus edodes) fruit bodies orally administered to mice. Chem. Pharm. Bull. (Tokyo) 35:2453-2458, 1987.	
	4	I. Hishida, H. Nanba, and H. Kuroda, Antitumor activity exhibited by orally administered extract from fruit body of Grifola frondosa (maitake). Chem. Pharm. Bull. (Tokyo) 36:1819-1827, 1988.	
	5	H. Nanba and H. Kuroda, Potentiation of host-mediated antitumor activity by orally administered mushroom (Agaricus bispora) fruit bodies. Chem. Pharm. Bull. (Tokyo) 36:1437-1444, 1988.	
	6	T. Ohmori, K. Tamura, A. Wakaiki, G. Kawanishi, S. Tsuru, T. Yadomae, and K. Nomoto, Dissociation of a glucan fraction (CO-1) from protein-bound polysaccharide of Cordyceps phloglossoides and analysis of its antitumor effect. Chem. Pharm. Bull. (Tokyo) 36:4512-4518, 1988.	
	7	H. Hanaue, Y. Tokuda, T. Machimura, A. Kamijoh, Y. Kondo, K. Ogoshi, H. Makuuchi, H. Nakasaki, T. Tajima, and T. Mitomi, Effects of oral lentinan on T-cell subsets in peripheral venous blood. Clin. Ther. 11:614-622, 1989.	
	8	I. Suzuki, K. Hashimoto, N. Ohno, H. Tanaka, and T. Yadomae, Immunomodulation by orally administered $\beta$ -glucan in mice. Int. J. Immunopharmacol. 11:761-769, 1989.	
	9	I. Suzuki, T. Sakurai, K. Hashimoto, S. Oikawa, A. Masuda, M. Ohsawa, and T. Yadomae, Inhibition of experimental pulmonary metastasis of Lewis lung carcinoma by orally administered $\beta$ -glucan in mice. Chem. Pharm. Bull. (Tokyo) 39:1606-1608, 1991.	
	10	T. Sakurai, K. Hashimoto, I. Suzuki, N. Ohno, S. Oikawa, A. Masuda, and T. Yadomae, Enhancement of murine alveolar macrophage functions by orally administered $\beta$ -glucan. Int. J. Immunopharmacol. 14:821-830, 1992.	

Examiner Signature		Date Considered	12/19/06
--------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/621,027
		Filing Date	July 16, 2003
		First Named Inventor	Nai-Kong CHEUNG
		Art Unit	
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	639-B-PCT-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ESO	11	K. Hayakawa, N. Mitsuhashi, Y. Saito, M. Takahashi, S. Katano, K. Shiojima, M. Furuta, and H. Niibe, Effect of krestin (PSK) as adjuvant treatment on the prognosis after radical radiotherapy in patients with non-small cell lung cancer. Anticancer Res. 13:1815-1820, 1993.	
	12	H. Hotta, K. Hagiwara, K. Tabata, W. Ito, and M. Homma, Augmentation of protective immune responses against Sendai virus infection by fungal polysaccharide schizophyllan. Int. J. Immunopharmacol. 15:55-60, 1993.	
	13	H. Morinaga, K. Tazawa, H. Tagoh, A. Muraguchi, and M. Fujimaki, An in vivo study of hepatic and splenic interleukin-1 $\beta$ mRNA expression following oral PSK or LEM administration. Gann 85:1298-1303, 1984.	
	14	Y. Iino, T. Yokoe, M. Maemura, J. Horiguchi, H. Takei, S. Ohwada, and Y. Morishita, Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res. 15:2907-2911, 1995.	
	15	H. Nanba, Activity of maitake D-fraction to inhibit carcinogenesis and metastasis. Ann. N. Y. Acad. Sci. 768:243-245, 1995.	
	16	V. Vetvicka, et al., Soluble $\beta$ -Glucan Polysaccharide Binding to the Lectin Site of Neutrophil or Natural Killer Cell Complement Receptor Type2 (CD11b/CD18) Generates a Primed State of the Receptor Capable of Mediating Cytotoxicity of iC3b-Opsonized Target Cells. J. Clin. Invest., 98:50-61, 1996.	
	17	J. Yan, et al., $\beta$ -Glucan, a "Specific" Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11b/CD18)1. J. Immunology, 163:3045-3052, 1999.	
	18	Y. Xia, V. Vetvicka, J. Yan, M. Hanikyrova, T. Mayada and G.D. Ross, The $\beta$ -Glucan-Binding Lectin Site of Mouse CR3 (CD11b/CD18) and Its Function in Generating a Primed State of the Receptor That Mediates Cytotoxic Activation in Response to iC3b-Opsonized Target Cells1. J. Immunology, 162:2281-2290, 1999	
✓			

Examiner Signature	<i>Eric S. Olson</i>	Date Considered	12/19/06
--------------------	----------------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.